Navamedic

39,4 NOK +0,77 %

1 investor følger denne virksomhed

Navamedic is a Nordic pharma company and supplier of products in consumer health, medical nutrition for rare diseases, specialty pharma, and branded generics covering therapeutic areas such as obesity, women’s health, urology, and gastro. The products are distributed to hospitals and pharmacies. Navamedic is present in all Nordic countries, Benelux and Baltics, and sales in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and was founded in 1999.

Omsætning

382,14 mio.

EBIT %

11,63 %

P/E

21,88

Udbytteafkast, %

Kursmål

Anbefaling

Opdateret

Oslo Børs

NAVA

Daglig lav / høj pris

38,6 / 39,5 NOK

Markedsværdi

678,77 mio. NOK

Aktieomsætning

79,33 t NOK

Volumen

2 t

Finanskalender

Delårsrapport

11.08.2023

Delårsrapport

01.11.2023

Viser Alle indholdstyper

Navamedic ASA: Minutes of Annual General Meeting

Selskabsmeddelelse01.06.2023

Navamedic

Finanskalender

Navamedic ASA: Minutes of Annual General Meeting

Navamedic ASA: Minutes of Annual General Meeting

NAVA: Updated recommendation by the nomination committee of Navamedic ASA

Updated recommendation by the nomination committee of Navamedic ASA

NAVA: Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Navamedic ASA: Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Navamedic ASA: Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

Navamedic ASA: Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

Navamedic ASA: Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

Navamedic ASA: Notice of Annual General Meeting

Navamedic ASA: Notice of Annual General Meeting

Navamedic ASA Q1 2023: Another strong quarter

Navamedic ASA Q1 2023: Another strong quarter

NAVA: Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

Navamedic ASA: Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

Navamedic ASA: Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

Navamedic ASA: Invitation to 2023 1st quarter presentation

Navamedic ASA: Invitation to 2023 1st quarter presentation

Navamedic ASA: Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

Navamedic ASA: Annual Report for 2022